GILD Q2 Revenue Hits $7.8B, GAAP Swings to $8.45 Loss on Deals

Gilead Sciences (GILD) reported Q2 2026 revenue of $7.8 billion, up 10% year over year, but GAAP diluted EPS swung to a loss of $(8.45) per share. The loss was driven entirely by $9.08 per share in one-time acquired IPR&D and tax expenses from the Arcellx, Tubulis, and Ouro Medicines acquisitions plus an Immunomedics impairment. GILD closed at $131.99 with a market cap of $167.9 billion.

The numbers

• Revenue: $7.8 billion (+10% YoY)
• Base business (ex-Veklury): +10%
• GAAP EPS: $(8.45)
• HIV sales: $5.7 billion (+12%)
• Biktarvy: $3.8 billion (+7%)
• Descovy: $967 million (+48% on PrEP demand)
• Trodelvy: $457 million (+26%)
• Yeztugo (lenacapavir PrEP): on track for ~$1B first year
• Operating cash flow: $6.1 billion

What the numbers mean

The headline GAAP loss masks an underlying business growing at its fastest rate in three years. HIV is the engine. Biktarvy at $3.8 billion continues to dominate the treatment market. Descovy’s 48% growth reflects accelerating PrEP demand, and Yeztugo (lenacapavir for PrEP) is tracking toward $1 billion in its first full year.

The cash burn is eye-popping: $11.3 billion in acquisition spending in six months, leaving $3.2 billion from $10.6 billion at year-end. But management pointed to $6.1 billion in operating cash flow and raised full-year base business guidance by $750 million versus February. The business is generating enough cash to fund the acquisition spree, but the runway is narrowing.

The August 27 bictegravir/lenacapavir single-tablet PDUFA resolved with approval: the FDA cleared Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg) on the PDUFA date, the smallest single-tablet HIV regimen ever (see our Bixlenvo coverage). For context on Gilead’s HIV franchise strategy, see our bic/len cannibalization analysis.

The acquisition pipeline

Gilead is executing a high-stakes transformation: spending billions on Arcellx (CAR-T for myeloma), Tubulis (ADCs), and Ouro Medicines (immunology) while the core HIV franchise prints cash. Anito-cel, the Arcellx CAR-T, is approaching its PDUFA. For the full analysis of that catalyst, see our anito-cel BCMA CAR-T PDUFA analysis.

The question for investors: can the acquisition pipeline deliver before the cash runs too low? The $6.1 billion in operating cash flow says they have runway. The $7.4 billion cash drain in six months says they are spending it fast.

Risk to watch

The August 27 bic/len PDUFA resolved cleanly with the Bixlenvo approval, removing the CRL risk that was the near-term threat to the HIV franchise’s growth trajectory. The base business needs to keep printing cash for the pipeline bets to pay off.

Source: Gilead Q2 2026 earnings release

What It Means for the Trade

The accounting story and the operating story are completely different, and confusing them is the mistake. GAAP EPS of $(8.45) is an artifact: $9.08 per share of acquired-IPR&D charges and tax items from the Arcellx, Tubulis, and Ouro deals plus an Immunomedics impairment are non-cash purchases of pipeline — accounting noise, not deterioration. The operating reality is a business growing 10% with $6.1 billion in quarterly operating cash flow and a raised guidance. That said, GAAP losses are not literally free: they mark what management paid for what they bought, and at some price those deals were bad deals regardless of accounting treatment.

At $131.99 and a $167.9 billion cap, GILD trades on whether the acquisition spree converts. The cash position tells the tension: $10.6 billion at year-end down to $3.2 billion in six months. Operating cash flow at $6.1 billion a quarter rebuilds the balance sheet fast — that is the strong-form version of the story — but it also means the next sizable deal needs either patience or the capital markets.

Mechanism and Market Context

The HIV franchise is the cash engine and it is still accelerating. Biktarvy at $3.8 billion dominates treatment; Descovy’s 48% PrEP growth shows demand elasticity; and Yeztugo’s ~$1 billion first-year trajectory is the structural story — twice-yearly lenacapavir PrEP is the most consequential HIV product of the decade. The Bixlenvo approval (August 27) is deliberately self-cannibalizing: bictegravir/lenacapavir is the bridge that keeps single-tablet patients inside Gilead’s tent as Biktarvy ages toward its patent horizon. Cannibalizing your own franchise before a generic does it to you is the right play; the models will fight about the margin mix for years.

The acquired pipeline is the bet. Arcellx’s anito-cel approaches its PDUFA in BCMA myeloma — a CAR-T race against Carvykti’s established position. Tubulis’s ADCs enter a field where Trodelvy (+26%) has been a persistent underperformer against Enhertu-class competition. Ouro Medicines is early-stage immunology. None of these is a sure thing; collectively they are a portfolio of shots funded by the strongest cash-flow business in the sector.

Risks and What Could Go Wrong

1. Anito-cel execution. The Arcellx PDUFA is the nearest conversion test; a delay or a narrow label deflates the most tangible acquisition payoff.
2. Cash runway discipline. Another $7-11 billion acquisition half-year would exhaust the buffer even at current cash generation.
3. HIV pricing politics. Yeztugo’s launch economics depend on access programs and payer negotiations that have not fully played out.
4. Trodelvy’s trajectory. If the Immunomedics impairment was the beginning rather than the end of that reckoning, the ADC story needs Tubulis to work.

The stock is a cash-compounder with optionality attached; the GAAP loss tells you the option premium, not the business health.